Loading...
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis
SUMMARY: The RisedronatE and ALendronate (REAL) study provided a unique opportunity to conduct cost-effectiveness analyses based on effectiveness data from real-world clinical practice. Using a published osteoporosis model, the researchers found risedronate to be cost-effective compared to generic o...
Na minha lista:
| Udgivet i: | Osteoporos Int |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2007
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5104544/ https://ncbi.nlm.nih.gov/pubmed/18008100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-007-0504-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|